Samenvatting
samenvatting nutrition and cancer
samenvatting van het vak nutrition and cancer
[Meer zien]Voorbeeld 3 van de 18 pagina's
Voorbeeld 3 van de 18 pagina's
In winkelwagengesponsord bericht van onze partner
Voorbeeld van de inhoud
Nutrition and cancer HNH-37806Week0
Study designs
Observational study
- Cross-sectional study
- Cohort study
- Case control study
Experimental study
- Randomized controlled trial
Cross-sectional study:
- Gather data on exposure and disease
Cohort study:
- Defined population
- Choice or circumstance
- Exposed vs not exposed
- Prospective: forward in time = longitudinal
- Direction of inquiry
Case-control study:
- Start with disease
- Retrospective-back in time
- Direction of inquiry
Experimental study / trial: clinical trial / randomized control trial
- Random allocation
- Investigator decides who gets the exposure
- Forward in time
- Direction of inquiry
Week1
Hallmarks of cancer
Clip 1
4 hallmarks directly related to growth and survival
- Sustaining proliferative signaling (growth)
- Evading growth suppressors (growth)
- Resisting cell death (survival)
- Enabling replicative immortality (survival)
Sustaining proliferative signaling = chronic proliferation: growth factors
- Increasing synthesis of growth factors by tumor cells
- Increasing synthesis of growth factors by neighboring cells
- Increasing receptors at cell surface
- Structural alterations receptors increase response
- Activation downstream pathway
Mutation in receptor: always active -> sending chronic signals to nucleus that proliferation
should be stimulated
1
,Evading growth suppressors: escape stop signal proliferation suppressors = tumor
suppressor gene
RB protein: prevents cancer cells from entering S-fase -> cancer cells mutation in RB -> RB
always inactive.
Clip 2:
Resisting cell death:
Cell death: apoptosis & autophagy ( = programmed), necrosis (acute damage; cell explodes)
Cancer cell deaths: apoptosis and autophagy decrease and necrosis increases.
P53 = damage sensor -> screens for damage in cell (G1) -> apoptosis in case of damage
Cancer cells p53 is inactivated -> no programmed cell death
Enabling replicative mortality = unlimited replication
- Telomere shortening
- Senescence (viable, non-proliferative state)
- Crisis (death)
Normal cell Cancer cell
Limited replication Immortalization
Shortening of telomeres Extending telomeres
Senescence/ apoptosis Alive (immortalized)
Telomerase absent / low Telomerase high
Clip 3:
Cancer cells: disseminate (spread)
Inducing angiogenesis & activating invasion and metastasis
Inducing angiogenesis
- Nutrient and oxygen supply
- Target for therapy
- Example: oncogenic stimuli -> increase VEGF -> neovascularization -> allow
metastasis
Activating invasion and metastasis = spread of cancer cells
- Via blood / lymph
Invasion-metastasis cascade
Primary tumor formation -> local invasion -> intravasation -> survival in circulation -> arrest
at distant organ site -> extravasation -> micro metastasis formation -> metastatic
colonization -> clinically detectable macroscopic metastasis
Malignant tumor = starts invading surrounding tissues or structures
EMT- epithelial-to-mesenchymal transition
(physiological process) -> phenotype of cell changes
Epithelial cells become mesenchymal cells
(carcinomas: cancers that arise from epithelial cells)
- Reverse process is MET
2
, Clip 4
Enabling and emerging characteristics
- Enabling: two additional characteristics that facilitate the other hallmarks
- Emerging: these potential hallmarks are emerging and not yet fully validated
Enabling characteristics:
Genome instability and mutation:
- Tumor suppressor genes: normal genes whose absence can lead to cancer
- Oncogens: are mutated genes whose presence can stimulate the development of
cancer
P53 = tumor suppressor gene
EGFR= oncogene
RB= tumor suppressor gene
Driver vs passenger concept
Passengers:
- Passenger mutation has no effect on neoplastic process
- Number of passenger mutation correlates with age
- Predominantly in self-renewing tissues (fast proliferating)
Drivers:
- Driver gene mutation = mutation conferring a selective growth advantage for the cell
- Impacts ratio cell birth: cell death
Tumor-promoting inflammation
- Infiltration of immune cells
- Supplying bioactive molecules to microenvironment
- Tumor inhibition as well as tumor promotion
Emerging characteristics:
Deregulating cellular energetics:
- Metabolic reprogramming for energy requirements
Avoiding immune destruction
- Escape immune surveillance
- T lymphocytes and NK cells
- Mechanisms are emerging
APC = TSG
MYC= ONC
BRCA1/2 = TSG
RAS = ONC
Clip 5:
Markers for proliferation: Ki67 protein
Struggles and limitations:
- Collection / timing / freezing
- Healthy subjects / patient’s
- Pain / anxiety / complications
- Complex datasets / timing
3
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper v7777777. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €6,89. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 64438 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen